
jul pm et
summari compani develop novel antibodi therapeut target varieti rare sever
diseas state includ autoimmun disord inflamm cancer
nm price-to-earnings oper ep
risk assess reflect view
depend expand number approv use
soliri support premium valuat mani new
explor indic earli middl stage
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
jul stock trade
look sale rise
soliri sale growth moder
growth
respect see strensiq sale
kanuma sale slower uptak
price concern
februari
reach fund agreement england
strensiq becam effect novemb
deal franc becam effect
top-lin phase switch data
show patient
effect safe switch treatment
soliri everi two week treatment
show non-inferior soliri primari
endpoint four secondari endpoint
safeti profil consist
soliri total data favor
soliri file approv
treat phn
europ expect file japan
uncertain mani patient
switch soliri
think share trade
forward ep estim
slightli peer near fair valu
balanc faster growth rate
risk heavi depend soliri
octob fda approv soliri
treatment gener myasthenia gravi
spite phase trial fail meet
primari endpoint met secondari
endpoint think safeti profil soliri
high level unmet need
achiev secondari endpoint led
approv think indic like
increas soliri sale around
encourag recent
regulatori file treat pnh
debilit potenti life-threaten
rare blood disord phase trial
treat atyp hemolyt urem
syndrom ahu on-going expect
data earli
risk recommend target price
includ slower-than-anticip sale soliri
pipelin failur includ
target price base
peer forward ep
estim posit view rare
diseas franchis pipelin
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice presid
independ chairman
board
corpor overview develop novel antibodi therapeut target
varieti sever disord includ autoimmun cardiovascular diseas inflamm cancer
first market product soliri eculizumab first therapi approv treatment patient
paroxysm nocturn hemoglobinuria pnh soliri design inhibit specif aspect
complement compon immun system therebi treat inflamm associ chronic
hematolog neurolog disord transplant reject autoimmun disord
soliri human monoclon antibodi complement inhibitor block cleavag compon
complement cascad prevent final stage complement activ soliri
develop treatment pnh rare blood disord caus anemia fatigu dark-color
urin hemoglobinuria pnh portion patient red blood cell miss complement inhibitor
caus abnorm fragil destroy normal complement activ
estim pnh patient european union japan said expect
pnh popul come rest world prior soliri
soliri also approv second indic rare kidney diseas atyp hemolyt urem syndrom
ahu often lead end-stag kidney diseas failur carri high mortal rate
septemb fda approv soliri use european union regul approv drug
novemb although ahu seen modest launch trajectori state
expect opportun rival pnh
strensiq asfotas alfa target enzym replac therapi approv therapi patient
hypophosphatasia design directli address underli caus aim restor
genet defect metabol process therebi prevent revers sever potenti
life-threaten complic patient food drug administr fda
approv strensiq patient perinatal- infantile- juvenile-onset european
commiss ec grant market author strensiq treatment patient
pediatric-onset ministri labour welfar mhlw approv strensiq
treatment patient compani sponsor multi-national registri gather inform
regard natur histori patient long-term outcom strensiq
kanuma sebelipas alfa recombin form human lal enzym enzyme-replac
therapi approv treatment patient lal-d fda approv kanuma
treatment patient lal-d ec grant market author kanuma long-term
enzym replac therapi patient age lal-d mhlw approv kanuma
treatment patient age japan lal-d compani sponsor multi-national
registri gather inform regard natur histori patient lal-d long-term
outcom kanuma treatment
pipelin long-act inhibitor work inhibit protein termin
complement cascad earli studi demonstr sustain reduct free level
alexion complet enrol four on-going clinic studi patient pnh
includ open-label phase i/ii dose-escal studi evalu safeti toler efficaci
pharmaco-kinet pk pharmaco-dynam pd administ intraven iv
infus phase ii open-label studi evalu efficaci safeti toler immunogen pk
pd administ iv infus investig multipl dose interv four twelv
week phase open-label random active-control multicent studi evalu safeti
efficaci versu eculizumab administ iv infus adult patient pnh
never receiv treatment complement inhibitor phase open-label random
active-control multicent studi evalu safeti efficaci versu eculizumab
administ iv infus adult patient pnh treat eculizumab least
past month
impact major develop june acquir synageva biopharma geva nr
billion consist cash share geva share geva
focus rare diseas geva kanuma treatment lysosom acid lipas defici orphan
drug statu us eu
financi trend sale risen billion billion repres
three-year compound annual growth rate compound-annual-growth-rate gross margin rang
 cost rose million sale million
sale adjust ep risen repres three-year
compound-annual-growth-rate
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
bullish sinc juli technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
biotechnolog sub-industri next
month reflect favor prospect new
novel therapi reach commerci yet
anticip modest overal
sale growth mainli due forecast
mid-teen sale declin
biotech sale rose low singl
digit follow growth
follow robust growth period
compound annual growth
rate think sale growth
somewhat limit heighten focu high
drug price encourag view
strong period report
late-stag clinic result
accommod fda approv
fda approv new drug --
sinc record approv
howev fda approv
new drug significantli robust
new drug approv think mani
newly-approv drug signific
commerci prospect repres major
advanc therapi diseas
sclerosi cancer fda
approv first time gene-therapi drug
involv remov patient immun cell
genet alter alter
cell re-introduc patient
help fight cancer
expect wider adopt biomark research
genetic-target clinic studi help
late fda introduc breakthrough
therapi design intend speed
develop promis program expect
favor merger acquisit climat
larg pharmaceut firm move off-set
lost revenu expir drug patent
larg biotech bolster drug pipelin amid
larger scale acquisit
fda author govern biosimilar
drug approv set exclus
advanc modest rate next
sever year see improv
biosimilar approv introduc
march fda approv novarti
filgrastim biosimilar version
novarti began sell
biosimilar name zarxio septemb
april fda approv
inflectra manufactur celltrion
co-market inflectra
biosimilar johnson johnson
expect biosimilar sell modest price
discount gener pharmaceut
industri due higher clinic manufactur
market cost expect brand
drug retain signific market share due
lack interchang think
biosimilar may appeal new user
expect current user stabl
current treatment would like continu
refer drug howev note
prescript benefit manag health
insur exert influenc drug
prescript price
remov neupogen formulari
replac zarxio
 biotech index rose vs
rise year date
juli biotech index
rose vs rise
base index
five-year market price perform jul
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
keep target price
peer ep estim faster growth ep
vs estim sale rose aid
chang revenu recognit certain non-u market soliri sale rose
million streniq sale million compar million year
ago better anticip driven new patient initi howev
expect pricing-per-pati lower due lower price negoti uk
regul increas access strensiq on-going /jeffrey loo cfa
inc lower
target peer ep estim
set ep estim although see sale
growth moder still see above-industri growth rate look
soliri grow growth
respect sale newer drug strensiq kanuma
achiev sale respect see slower uptak
price concern recommend limit usag strensiq
recommend kanuma high price /jeffrey loo cfa
analyst research note compani news
rais target price
slightli peer forward ep estim
see grow faster peer posit view
rare diseas pipelin ep vs ahead
estim rais ep estim ep
estim sale rose volum rose driven
robust launch soliri treat gener myasthenia gravi gmg overal
soliri sale rose volum growth strensiq sale rose
kanuma sale rose encourag pipelin progress
file approv treat paroxysm nocturn hemoglobinuria
pnh europ expect file japan phase
trial treat atyp hemolyt urem syndrom ahu
on-going expect data earli /jeffrey loo cfa
keep target price
slightli peer ep estim
ep vs ahead estim sale rose
soliri sale strensiq kanuma share
significantli follow posit top-lin phase switch
clinic trial data show patient paroxysm
nocturn hemoglobinuria pnh effect safe switch treatment
soliri everi two week treatment everi eight week studi
show non-inferior soliri primari endpoint four
secondari endpoint safeti profil consist soliri
believ total data favor soliri
plan file regulatori submiss europ
japan howev uncertain mani patient
stabl soliri make switch /jeffrey loo cfa
inc lower target
slightli above-p ep estim
set ep ep vs ahead
estim sale rose soliri sale strensiq
kanuma much lower base guid sale
soliri sale ep expect data
phase trial treat paroxysm nocturn
hemoglobinuria pnh debilit potenti life-threaten rare
blood disord /jeffrey loo cfa
keep target
peer forward ep ep vs
ahead view rais ep estim
sale rose soliri sale
strensiq kanuma rose much smaller base see steadi
growth soliri sale fda emea approv addit
indic also look improv strensiq sale fund deal
england becom effect novemb new agreement franc becom
effect /jeffrey loo cfa
inc rais target
peer forward ep estim
ep vs ahead estim rais ep
estim soliri sale rose
volum rose strensiq sale rose
encourag alxn fund deal nation
base manag access agreement provid strensiq
patient pediatr onset hypophosphatasia kanuma sale
view /jeffrey loo cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
